Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study With Open-Label Extension to Evaluate the Safety and Efficacy of ST266 Eye Drops in the Treatment of Persistent Corneal Epithelial Defects

NCT05066698 is registered in ClinicalTrials.gov with Noveome Biotherapeutics, formerly Stemnion as lead sponsor.

NCT NCT05066698
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05066698 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study With Open-Label Extension to Evaluate the Safety and Efficacy of ST266 Eye Drops in the Treatment of Persistent Corneal Epithelial Defects
Lead sponsor
Noveome Biotherapeutics, formerly Stemnion
Phase
Phase 2
Overall status
Terminated
Start date
April 27, 2022
Completion date
September 7, 2022
Enrollment
8 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

persistent corneal epithelial defect